EBITDA +6% vs ABGSC and EBIT turned positive in Q3 We expect consensus to lift 2024 EBITDA by 10-15%...
Relais reported Q3 adjusted EBITA of EUR 9.2m, 9% below LSEG Data & Analytics consensus.
Redeye provides an initial take following the release of Optomed’s Q3 2024 report.
Sales SEK 344m -9% vs. ABGSCe 377m EBIT adj. for FX and cyberattack ~SEK -3m vs.
Q3 adj. EBIT of SEK 32m, +1% vs. ABGSC AUM flat q-o-q when adjusting for FX headwinds Q3 in line wit...
Redeye provides an initial comment on the Q3 2024 report from Catella.
CapMan reported Q3 adjusted EBIT of EUR 2.0m, 23% below LSEG Data & Analytics consensus, most of whi...
Redeye updates its valuation model following Xspray's announcement of SEK235m in financing and the c...
Redeye comments on Medivir's Q3 report. We make changes to our base case as IGM Biosciences exits on...
Redeye provides an update following Neola Medical’s Q3 2024 report.
Redeyes view on the announced sizable order from a German operator.
Redeye gives a brief comment on today’s news regarding Tesofensine, indicating that Tesofensine has ...
Tessin tillhandahåller en digital investeringsplattform för säkerställda fastighetslån.
Suominen’s revenue grew 5% y/y in Q3, which was below estimates.
Marimekko's third quarter revenue was in line with our estimates, yet profitability fell a tad short...
STENOCARE published on November 5th the company’s Q3-report for 2024.
Potentiell vändpunkt Adtraction minskade omsättningen med 17,5 procent i det tredje kvartalet.
Solid Q3, particularly on EBITA margins Price hikes to help margins in Q4e and beyond Expect cons to...
Coor rapporterade ett kvartal under Analysguidens förväntan.
iZafe Group levererade ett kvartal i linje med Analysguidens prognos.
